Articles From: Forest Laboratories Names Brent Saunders CEO and President to Forest Labs swings to profit, raises full-year view


Forest Laboratories, Inc. (NYSE:FRX) today announced that Brenton L.
Sign-up for Forest Laboratories Names Brent Saunders CEO and President investment picks
Forest Laboratories, Inc. (NYSE:FRX) today announced that Karen Ling was appointed Senior Vice President and Chief Human Resources Officer.
Sign-up for Forest Laboratories Names Karen L. Ling Senior Vice President, Chief Human Resources Officer investment picks
Forest Laboratories, Inc. (NYSE:FRX) announced today that it has submitted to the Food and Drug Administration (FDA) data from its pediatric program to extend the Namenda (memantine HCI) U.S. patent 5,061,703. If the FDA finds that the submission meets the requirements of the Pediatric Written Request, the company would be entitled to a six-month extension of marketing exclusivity for Namenda after the expiration of the patent on April 11, 2015 to October 11, 2015.
Sign-up for Forest Laboratories Pursues Additional Market Exclusivity to Extend Namenda Patent investment picks
2014/2/18
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Forest Laboratories, Inc. (“Forest Laboratories”) (NYSE: FRX) related to the sale of FRX to Actavis PLC in an acquisition valued at approximately $25 billion.
Sign-up for Forest Laboratories Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Actavis investment picks
2014/2/27
Forest Laboratories, Inc. (NYSE:FRX) announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for a fixed dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
Sign-up for Forest Laboratories Submits a New Drug Application for Nebivolol and Valsartan Combination in Hypertension investment picks
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal (GI) and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm.
Sign-up for Forest Laboratories to Acquire Aptalis for $2.9 Billion in Cash investment picks
2014/2/14
Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA ® (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.
Sign-up for Forest Laboratories to Discontinue NAMENDA® Tablets, Focus on Once-Daily NAMENDA XR® investment picks
2014/1/21
By Ben Eisen, MarketWatch NEW YORK (MarketWatch) -- Forest Laboratories Inc. shares surged after a strong earnings report, while Amarin Corp.
Sign-up for Forest Laboratories up on earnings, Amarin sinks investment picks
2014/2/18
By Ben Eisen, MarketWatch NEW YORK (MarketWatch) -- Actavis PLC said Tuesday it would buy Forest Laboratories Inc., sending both pharmaceutical stocks sharply higher in premarket trade.
Sign-up for Forest Laboratories, Actavis surge on buyout deal investment picks
2014/3/21
Forest Laboratories, Inc. (NYSE:FRX) and Gedeon Richter Plc.
Sign-up for Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Positive Phase IIb Topline Results for Cariprazine as Adjunctive Therapy in the Treatment of Major Depressive Disorder investment picks
2014/3/31
Forest Laboratories, Inc. (NYSE:FRX) and Gedeon Richter Plc.
Sign-up for Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Positive Phase IIb Topline Results for Cariprazine for the Treatment of Bipolar Depression investment picks
2014/1/27
Forest Laboratories, Inc. (NYSE:FRX) (“Forest Laboratories”) today announced a proposed offering of $1.8 billion aggregate principal amount of senior unsecured fixed rate notes in two tranches, with one tranche due 2019 and the other tranche due 2021 (together, the “notes”). The precise timing, size, and terms of the offering are subject to market conditions and other factors.
Sign-up for Forest Laboratories, Inc. Announces Private Placement of Senior Notes investment picks
2013/12/2
Forest Laboratories, Inc. (NYSE:FRX) (“Forest Laboratories”) today announced a proposed offering of $1 billion aggregate principal amount of senior unsecured fixed rate notes due 2021 (the “notes”). The precise timing, size and terms of the offering are subject to market conditions and other factors.
Sign-up for Forest Laboratories, Inc. Announces Private Placement of Senior Notes and Amendment to Existing $750 Million Revolver investment picks
Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd.
Sign-up for Forest Laboratories, Inc. Announces Settlement of BYSTOLIC® Patent Litigation investment picks
2014/2/3
Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company, today announced the completion of its acquisition of Aptalis, a privately held specialty pharmaceutical company focused on gastrointestinal disorders and cystic fibrosis.
Sign-up for Forest Laboratories, Inc. Completes $2.9B Acquisition of Aptalis investment picks
2013/10/2
Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd.
Sign-up for Forest Laboratories, Inc. Files Additional Lawsuit against First Time US Generics LLC for Infringement of SAVELLA® Patents investment picks
2014/1/31
Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd.
Sign-up for Forest Laboratories, Inc. Files Lawsuit Against Several Companies for Infringement of NAMENDA XR® Patents investment picks
Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd.
Sign-up for Forest Laboratories, Inc. Files Lawsuits against Several Companies for Infringement of Savella® Patents investment picks
2014/2/24
Forest Laboratories, Inc. (NYSE:FRX) today announced the launch of the STRIDE ( S tart T reatment, R eal-time I nformation, D isease Ed ucation ) patient support program to help those prescribed Tudorza® Pressair® (aclidinium bromide inhalation powder) or Daliresp® (roflumilast) by answering questions they may have about their chronic obstructive pulmonary disease (COPD) treatment.
Sign-up for Forest Laboratories, Inc. Launches STRIDE Patient Support Program for COPD Franchise Products Tudorza® Pressair® and Daliresp® investment picks
2014/1/27
Forest Laboratories, Inc. (NYSE:FRX) (“Forest Laboratories”) today announced it priced a private placement offering $1.8 billion aggregate principal amount of senior unsecured notes, comprised of $1.05 billion aggregate principal amount of its 4.375% senior unsecured notes due 2019 (the “2019 senior notes”) and $750 million aggregate principal amount of its 4.875% senior unsecured notes due 2021 (the “2021 senior notes” and together with the 2019 senior notes, the “notes”). The 2019 senior notes will bear an interest rate of 4.375% per annum and will be issued at a price of 100.000% of the aggregate principal amount.
Sign-up for Forest Laboratories, Inc. Prices Offering of $1.8 Billion in Senior Notes investment picks
Forest Laboratories, Inc. (NYSE:FRX), an international pharmaceutical manufacturer and marketer, today announced that reported diluted earnings per share equaled $0.26 in the second quarter of fiscal 2014.
Sign-up for Forest Laboratories, Inc. Reports Fiscal Year Second Quarter 2014 Diluted Earnings Per Share of $0.26 Including Effect of $0.10 Per Share of Acquisition Amortization investment picks
2014/1/21
Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013.
Sign-up for Forest Laboratories, Inc. Reports Fiscal Year Third Quarter 2014 investment picks
2014/4/1
Forest Laboratories, Inc. (NYSE:FRX), a leading fully integrated, specialty pharmaceutical company largely focused on the United States market, will release its Fiscal 2014 Fourth Quarter financial results before the U.S. stock market opens on Tuesday, April 29, 2014.
Sign-up for Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Fourth Quarter Earnings investment picks
Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2014 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 22, 2013.
Sign-up for Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Second Quarter Earnings investment picks
Forest Laboratories, Inc. (NYSE:FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2014 Third Quarter financial results before the U.S. stock market opens on Tuesday, January 21, 2014.
Sign-up for Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Third Quarter Earnings investment picks
2014/2/19
Rigrodsky & Long, P.A.: Do you own shares of Forest Laboratories, Inc. (NYSE: FRX )? Did you purchase any of your shares prior to February 18, 2014?
Sign-up for FOREST LABORATORIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/2/18
Rigrodsky & Long, P.A.: Do you own shares of Forest Laboratories, Inc. (NYSE: FRX )? Did you purchase any of your shares prior to February 18, 2014?
Sign-up for FOREST LABORATORIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/2/19
DALLAS , Feb.
Sign-up for Forest Laboratories, Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover investment picks
Forest Laboratories, Inc. (NYSE:FRX) (“Forest Laboratories”) today announced it upsized and priced a private placement offering of $1.2 billion aggregate principal amount of its 5.00% senior unsecured notes due 2021 (the “notes”). The size of the offering was increased to $1.2 billion from the previously announced $1 billion.
Sign-up for Forest Laboratories, Inc. Upsizes and Prices Offering of $1.2 Billion of Senior Notes Due 2021 investment picks
2014/1/21
By Everdeen Mason NEW YORK --
Sign-up for Forest Labs swings to profit, raises full-year view investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Forest Laboratories Names Brent Saunders CEO and President to Forest Labs swings to profit, raises full-year view
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity